Roche is implementing a new operating model for its global R&D activities organized around Disease Biology Areas (DBA) that will cover R&D through to marketing. The Disease Biology Area Leadership Teams (DBLTs) will be co-located in Basel, Switzerland, Nutley, NJ and Palo Alto, CA. The company’s R&D efforts will focus on clinically differentiated medicines for the following therapeutic areas: oncology, based in Nutley, virology and inflammation, based in Palo Alto, metabo...